PMID- 27766728
OWN - NLM
STAT- MEDLINE
DCOM- 20171107
LR  - 20220408
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 19
IP  - 3
DP  - 2017 Mar
TI  - Effects of once-weekly dulaglutide on kidney function in patients with type 2 
      diabetes in phase II and III clinical trials.
PG  - 436-441
LID - 10.1111/dom.12816 [doi]
AB  - Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist approved 
      for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and 
      III trials in people with T2D (N = 6005) were used to evaluate the effects of 
      dulaglutide on estimated glomerular filtration rate (eGFR [Chronic Kidney Disease 
      Epidemiology Collaboration]), urine albumin-to-creatinine ratio (UACR) and kidney 
      adverse events (AEs). No significant differences in eGFR were observed during 
      treatment for dulaglutide vs placebo, active comparators or insulin glargine 
      (mean +/- standard deviation values: dulaglutide vs placebo: 87.8 +/- 17.7 vs 88.2 +/- 
      17.9 mL/min/1.73 m(2) , P = .075; dulaglutide vs active comparators: 89.9 +/- 16.7 
      vs 88.8 +/- 16.3 mL/min/1.73 m(2) , P = .223; and dulaglutide vs insulin glargine: 
      85.9 +/- 18.2 vs 83.9 +/- 18.6 mL/min/1.73 m(2) , P = .423). Lower UACR values were 
      observed for dulaglutide vs placebo, active comparators and insulin glargine (at 
      26 weeks, median [Q1-Q3] values were: dulaglutide vs placebo: 8.0 [4.4-20.4] vs 
      8.0 [4.4-23.9] mg/g, P = .023; dulaglutide vs active comparators: 8.0 [4.4-21.2] 
      vs 8.9 [4.4-27.4] mg/g, P = .013; and dulaglutide vs insulin glargine: 8.9 
      [4.4-29.2] vs 12.4 [5.3-50.5] mg/g, P = .029). AEs reflecting potential acute 
      renal failure were 3.4, 1.7 and 7.0 events/1000 patient-years for dulaglutide, 
      active comparators and placebo, respectively. In conclusion, dulaglutide 
      treatment of clinical trial participants with T2D did not affect eGFR and 
      slightly decreased albuminuria.
CI  - (c) 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
FAU - Tuttle, Katherine R
AU  - Tuttle KR
AD  - Providence Health Care, University of Washington, Spokane, Washington.
FAU - McKinney, T Dwight
AU  - McKinney TD
AD  - Eli Lilly and Company, Indianapolis, Indiana.
FAU - Davidson, Jaime A
AU  - Davidson JA
AD  - Touchstone Diabetes Center, University of Texas Southwestern Medical Center, 
      Dallas, Texas.
FAU - Anglin, Greg
AU  - Anglin G
AD  - Eli Lilly Canada, Toronto, Ontario, Canada.
FAU - Harper, Kristine D
AU  - Harper KD
AD  - Eli Lilly and Company, Indianapolis, Indiana.
FAU - Botros, Fady T
AU  - Botros FT
AD  - Eli Lilly and Company, Indianapolis, Indiana.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20161124
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - AYI8EX34EU (Creatinine)
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
MH  - Acute Kidney Injury/*chemically induced/metabolism
MH  - Aged
MH  - Albuminuria
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Creatinine/urine
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Glucagon-Like Peptides/*analogs & derivatives/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Immunoglobulin Fc Fragments/*therapeutic use
MH  - Insulin Glargine/therapeutic use
MH  - Kidney Function Tests
MH  - Male
MH  - Middle Aged
MH  - Recombinant Fusion Proteins/*therapeutic use
MH  - Treatment Outcome
PMC - PMC5347883
OTO - NOTNLM
OT  - GLP-1
OT  - clinical trial
OT  - diabetes complications
OT  - diabetic nephropathy
OT  - dulaglutide
OT  - type 2 diabetes
EDAT- 2016/10/22 06:00
MHDA- 2017/11/08 06:00
PMCR- 2017/03/13
CRDT- 2016/10/22 06:00
PHST- 2016/06/09 00:00 [received]
PHST- 2016/10/06 00:00 [revised]
PHST- 2016/10/17 00:00 [accepted]
PHST- 2016/10/22 06:00 [pubmed]
PHST- 2017/11/08 06:00 [medline]
PHST- 2016/10/22 06:00 [entrez]
PHST- 2017/03/13 00:00 [pmc-release]
AID - DOM12816 [pii]
AID - 10.1111/dom.12816 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2017 Mar;19(3):436-441. doi: 10.1111/dom.12816. Epub 2016 
      Nov 24.